anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
It is disclosed a method for marketing vibration medicine products. The method includes getting an original liquid vibration medicine product, producing a powder vibration medicine product, providing that powder vibration medicine product for blending inside a food or drink entity to get a new entity, and marketing the new entity as an improved first entity. The original vibration medicine product includes essences, and is marketed as having properties associated with the essences. The production of the second product is done using the original vibration medicine product and an acceptable food carrier as raw materials. Consequently, the second product has some presence of the original essences. The second entity is improved over the first entity in its association with the first vibration medicine product.
FIELD: stomatology; compositions for hygiene of oral cavity. SUBSTANCE: cleaner may be in the form of paste or gel, or gel containing triclosan, polishing agent, polyphosphonate, anionic or nonionic surface-active substance, gel-forming agent, diluent consisting of water and moistener; agent additionally has stabilizer or aromatizer and components given in determined ratio. Container for viscous agent for teeth cleaning comprises distributing device having discharging passage with nose and cover. Chamber for agent storage is formed by inner walls of container made from polymer which eliminates loss of active properties of above-described agent. EFFECT: higher efficiency. 7 cl, 2 dwg
Transcutaneous vagus nerve stimulation (tVNS) is a promising technique for enhancing cognitive performance and skill acquisition. Yet, its efficacy for enhancing learning rate and long-term retention in an ecologically valid learning environment has not been demonstrated. We conducted two double-blind sham-controlled experiments examining the efficacy of auricular tVNS (taVNS: Experiment (1) and cervical tVNS (tcVNS: Experiment (2), on a 5 day second-language vocabulary acquisition protocol among highly selected career linguists at the US Department of Defense's premier language school. tcVNS produced accelerated recall performance during training (Day 2-4), benefits of which were maintained across a 24 h retention interval with no stimulation at the final test. Consistent with prior work, tcVNS also produced fatigue-mitigating and focus-promoting effects as measured by the Air Force Research Laboratory Mood Questionnaire. Based on the current and the previous findings supporting tVNS' efficacy on performance, training enhancement, and fatigue mitigation, we believe tcVNS to be an effective learning acceleration tool that can be utilized at language-teaching and other institutions focused on intensive training of cognitive skills.
CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
<P>PROBLEM TO BE SOLVED: To identify a gene having cartilage differentiation-accelerating action and involved in osteopathy or arthropathy including osteoarthritis, to provide a method for screening substances inhibiting the gene's function, to provide screened substances, and to provide diagnostic means and medicines using these substances.  <P>SOLUTION: It has been found that Runx3 gene has the action of accelerating cartilage differentiation and is related to osteopathy or arthropathy including osteoarthritis. Therefore, substances that control the function of Runx3 can be served as pharmaceutical preparations for the above diseases. The method for screening such substances is also provided. Furthermore, by analyzing the expression of the Runx3 gene and a protein encoding the same, the diagnostic means or medicines for the above diseases are also provided respectively.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Adynamic bone disease may develop if iPTH levels are suppressed below 100 pg/mL. One clinical study evaluated bone histomorphometry in patients treated with cinacalcet tablets for 1 year. Three patients with mild hyperparathyroid bone disease at the beginning of the study developed adynamic bone disease during treatment with cinacalcet tablets. Two of these patients had iPTH levels below 100 pg/mL at multiple time points during the study. In three 6-month, phase 3 studies conducted in patients with CKD on dialysis, 11% of patients treated with cinacalcet had mean iPTH values below 100 pg/mL during the efficacy-assessment phase. If iPTH levels decrease below 150 pg/mL in patients treated with cinacalcet, the dose of cinacalcet tablets and/or vitamin D sterols should be reduced or therapy discontinued.
Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the "reflex Ridge" Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
PURPOSE:A cathartic to evacuate efficiently the bowels by a carbonic acid gas of lactose decomposition product without causing side effects, comprising lactose with specific particle diameters and a mold such as lactic acid bacteria, etc. to mulfiply by the use of lactose as a nutrition source. CONSTITUTION:A cathartic comprising lactose having particle diameters capable of passing through at least 150-250mum mesh as a main agent, and a mold (e.g., lactic acid bacteria, Lactobacillus bifidus, etc.) to multiply by the use of lactose as a nutrition source. The cathartic uses about 20-50g lactose as an amount for one dose, it is dissolved in about 200cc water or warm water, and processed into preferably at least 1.5-10.7CS viscosity. In an existing cathartic, undissolved lactose is deposited in the stomach, and causes side effects such as nausea, vomiting feeling, but the cathartic has the fittest particle diameters determined from solubility of lactose, good circulation from the stomach to the intestine, and can evolve efficiently a carbonic acid gas, etc. by fermentation in the intestine.
In recent years, nonsteroidal anti-inflammatory drug (NSAIDs), which are considered to affect the prognosis of spinal surgery, have been widely used in perioperative analgesia in spinal surgery, but the relationship between these two factors remains unclear. The purpose of this study was to explore the effect of perioperative use of NSAIDs on the prognosis of patients treated with spinal surgery. We systematically searched PubMed, Embase, and Cochrane Library for relevant articles published on or before July 14, 2023. We used a random-effect model for the meta-analysis to calculate the standardized mean difference (SMD) with a 95% confidence interval (CI). Sensitivity analyses were conducted to analyze stability. A total of 23 randomized clinical trials including 1457 participants met the inclusion criteria. Meta-analysis showed that NSAIDs were significantly associated with postoperative morphine use (mg) (SMD = -0.90, 95% CI -1.12 to -0.68) and postoperative pain (SMD = -0.71, 95% CI -0.85 to -0.58). These results were further confirmed by the trim-and-fill procedure and leave-one-out sensitivity analyses. The current study shows that perioperative use of NSAIDs appears to be an important factor in reducing postoperative pain and morphine use in patients undergoing spinal surgery. However, well-designed, high-quality randomized controlled trials (RCTs) are still required.
The invention belongs to the field of analysis of traditional Chinese medicines, and discloses a standard fingerprint spectrum of a Chinese medicinal composition, and a measurement method and application thereof. The standard fingerprint spectrum is a high performance liquid chromatography spectrum; six main chromatographic peaks are shown in the spectrum; the No. 3 peak is the chromatographic peak which has the same peak retention time as ferulic acid serving as a reference object; and compared with the No. 3 peak, the other five chromatographic peaks have the relative retention time of 0.23+/-10 percent, 0.27+/-10 percent, 1.20+/-8 percent, 1.65+/-10 percent and 1.80+/-10 percent respectively. The standard fingerprint spectrum can be used for quality control over the Chinese medicinal composition comprising szechuan lovage rhizome and tall gastrodia tuber serving as raw medicinal materials; and the similarity of the fingerprint spectrum of a qualified Chinese medicinal composition to the standard fingerprint spectrum is not less than 0.80. The standard fingerprint spectrum can completely and effectively control the product quality; a similarity evaluation system is adopted; and the invention has the advantages of convenience and high speed in operation and objective and accurate result.
The present invention discloses a ginsenoside product of monomer compatibility for improving the sextual function. The present invention is characterized in that the ginsenoside product of monomer compatibility comprises ginsenoside monomer Rg3, ginsenoside monomer RH1 and panaxadiol type saponin. The weight compounding ratio of the ginsenoside monomer Rg3 and the ginsenoside monomer RH1 is 1: (0.1-10), and the weight compounding ratio of the ginsenoside monomer Rg3 and the panaxadiol type saponin is 1: (0.1-10). The product can enhance male and female sexual functions and can mainly treat diseases, such as sexual impotence, prospermia, frigidity, soreness and weakness of the waist and the knees, prostatosis, urinary incontinence, etc. without side effect. Compared with the existing medicines for treating the diseases, the present invention has the advantages of favourable effect, short treating time and low expense and has the same efficiency of strengthening a body as the efficiency of ginseng. The present invention enlarges the use reange of ginseng and sufficiently utilizes the specific monomer saponin component in ginseng so that the application of ginseng is wider, more scientific and more reasonable.
Pharmacological or genetic inactivation of MAGL reduces neuroinflammation and neuropathology in animal models of AD. However, global inactivation of MAGL induces functional tolerance of CB1R, which reduces the effectiveness of pharmacotherapies. Moreover, it has been shown that global inactivation of MAGL induces some other adverse effects, including cognitive impairments (Figure 3), showing that global inactivation of MAGL with pharmacological inhibitors are not an optimal approach to achieve ideal therapeutic effects for AD. Other evidence has shown that selective inactivation of MAGL in astrocytes, but not in neurons, reduces neuropathology and synaptic and cognitive impairments in TBI. In particular, the results showed that inactivation of astrocytic MAGL attenuates AD neuropathology and prevents deterioration in LTP, spatial learning and memory in AD animals. This shows that neuroprotective effects of global MAGL inactivation largely result from limiting 2-AG degradation in astrocytes, rather than in neurons. Therefore, selective inactivation of astrocytic MAGL provides a better therapeutic outcome for AD, as this greatly minimizes the potential adverse effects resulting from global inactivation-induced disruption of 2-AG degradation in neurons and in other peripheral tissues. To this end, an AAV-mediated gene silencing approach to knock MAGL selectively in astrocytes is presented.
This is a randomized (treatment assigned by chance, like flipping a coin), multicenter, double-blind (neither physician nor patient will know the treatment the patient receives), parallel-group (each group of patients will be treated at the same time) study. JNJ-40346527 will be compared to a placebo, which is an inactive substance used to test whether a drug has a real effect. Patients will receive study medication for 12 weeks and will continue their permitted, stable DMARD therapy (methotrexate \[MTX\], sulfasalazine \[SSZ\], and/or hydroxychloroquine \[HCQ\]) through Week 12. A follow-up visit will occur 4 weeks after dosing is complete. The maximum length of patient participation will be 22 weeks, including a 6-week screening period. Other study visits will occur during the study, and patient safety will be monitored.
Gestational diabetes mellitus (GDM) portends an immediate, increased risk for Type 2 diabetes mellitus (T2DM). The increased risk associated with having GDM is compounded by excess weight retention, a common issue after any pregnancy. Considering excess weight is the best predictor of developing T2DM, the weeks and months immediately after a GDM-complicated pregnancy present an optimal window to initiate lifestyle changes to prevent or delay T2DM. The long-term goal is to prevent T2DM among women with GDM. This study's objective is to evaluate the efficacy of a novel, yet simple, activity-boosting intervention on weight loss among women with GDM in a parallel two-arm randomized controlled trial (n=80 women/arm, N=160). The intervention uses ankle weights (2.5 pounds \[1.1 kg\]) worn on each ankle during routine daily activities (e.g., cleaning, cooking, child care) to increase energy expenditure. The central hypothesis, based on existing literature and preliminary data, is that postpartum women with GDM will adopt an intervention that requires minimal additional time outside of their daily activities. We anticipate that this will result in additional weight loss that is clinically significant when compared with controls who only receive standard information on recommended physical activity. The rationale for the proposed research is that once an intervention that both improves T2DM factors and is easily adopted by women with GDM is known, early intervention specific to this restricted timeframe can be implemented.
As the number of people age 65 years old or older continues to increase, population aging has a profound impact on healthcare systems, and specifically the emergence of dementia in literally epidemic proportions. Numerous studies on the associations between grape consumption and dementia and Alzheimer's disease have found evidence to support the use of grapes and grape products as a safe and effective way to treat and delay the onset of dementia. For the present study, the Investigator aims (1) to identify regional cerebral metabolic changes associated with grape intake, (2) to determine whether the presence and magnitude of therapeutic responses to grape in patients undergoing neuroimaging evaluation for cognitive decline can be predicted by particular patterns of regional brain metabolism, and (3) to statistically assess the relationships between brain metabolism assessed by PET and cognitive function in randomized experimental arms. A total of 32 patients from a community sample of patients referred to UCLA NeuroPET Clinics by their neurologists for further evaluation by brain imaging will be studied in this placebo-controlled, double-blinded study. Subjects who have met the screening criteria will be randomized to receive 72 g of grape powder or placebo, reconstituted in water, per day. Regional brain metabolism will be measured with a PET scanner, and cognitive function will be measured by a neuropsychologic test battery assessed at baseline, 6 months following initiation of consumption, and 1 year following initiation of consumption of the grapes of placebo formulation.
The patient will give blood to grow T cells on either one to two separate occasions. Then, the EBV-specific T cells will be made. These cells will be grown and frozen. To get the HER2 antibody (and the CD28) and the DNR to attach to the surface of the EBV-T cells, the antibody gene and the DNR gene will be inserted into the EBV-T cell. This is done with two viruses called retroviruses that have been made for this study. One will carry the antibody gene into the T cell and the other the DNR gene.

When the patient is enrolled on the study, they will be assigned to a dose of HER2-DNR EBV-T cells. The subject will be given one dose of cells into the vein through an IV line. The injection will take between 1 and 10 minutes. The patient will be followed in the clinic after the injection for 1 to 4 hours. The treatment will be given by the Center for Cell and Gene Therapy at Texas Children's Hospital or Houston Methodist Hospital.
A notation assistant system has a machine learning system, a notation processing system, a scoring system, and a suggestion system. The machine learning system trains a classifier for rating a factor related to a clinical narrative note that describes a patient's health status. The notation processing system processes a clinical narrative note and the scoring system determines a factor rating, such as a completion score or a clarity score. The scoring system provides the factor rating to an end-user device to display to a user. The notation assistant system is configured to perform a method as a user is entering a clinical narrative note to provide real-time feedback, such as the factor rating. The suggestion system is configured to provide suggestions for modifying the clinical narrative note to improve the rating factor. The notation assistant system applies to patient health conditions such as a health status of a patient's heart for a patient receiving care for congestive heart failure.
Heart failure (HF) affects over 5 million adults over the age of 65. Cardiac transthyretin amyloidosis (ATTR-CM) is a cause of HF in \~10% of older adults and leads to significant morbidity and mortality. Exercise intolerance is traditionally attributed to cardiac dysfunction but the contribution of other systems to this has not been studied. Musculoskeletal involvement is common in ATTR-CM and occur 5-10 years prior to onset of HF. Tafamidis, a transthyretin stabilizer, is the only approved treatment for ATTR-CM. It slows disease progression, prolongs life, and reduces HF hospitalizations. However, it does not improve functional capacity- no therapeutic intervention has been shown to do so in ATTR-CM.

The idea behind this project is that skeletal muscle dysfunction from amyloidosis and HF severely limits exercise capacity and, thus, quality of life in ATTR-CM, and that targeted exercise training will improve quality of life by improving skeletal muscle performance and aerobic capacity. Cardiopulmonary exercise testing (CPET) and the short physical performance battery (SBBP), including a leg extensor muscle power assessment will be used to achieve the following specific aims; 1) to compare skeletal muscle performance in ATTR-CM and non-amyloid HF; and 2) to determine improvements in aerobic capacity and quality of life due to 12 weeks of supervised exercise training in patients with ATTR-CM. To achieve the second aim, we will use a personalized exercise intervention.
333369EPY2002 is the open-label extension study that follows the double-blind study 333369EPY2001. In an open label study such as 333369EPY2002, both the physician and the patient know the name of the assigned study medication. In a double blind study such as 333369EPY2001, neither the physician nor the patient knows the name of the assigned study medication. Patients who complete the double-blind treatment phase of study 333369EPY2001 will be eligible to enter the open-label extension study during which patients will transition through a blinded period to an open-label period with carisbamate (also referred to as RWJ-333369). RWJ-333369 is a new chemical compound with anticonvulsant activity that is currently under investigation as a treatment for epilepsy. Patients electing to enter the open-label extension phase will be supplied with both open-label carisbamate (RWJ-333369) and blinded study medication for the transition phase. During this transition phase (up to 21 days in length), the patient's dose of double-blind study drug will be gradually reduced and stopped and treatment with open-label RWJ-333369 will be started. Throughout the remainder of the open label extension phase, investigators will be allowed to make further adjustments of the dosage and schedule of carisbamate, including independent adjustment of the morning and evening doses, but a dosage of 1,200 mg/day may not be exceeded and increases in dosage must be in increments of no more than 200 mg/day. Patients who, in the judgment of the investigator, continue to benefit from treatment with RWJ-333369 may continue to receive the drug with follow up clinic visits every 3 months until RWJ 333369 is available by prescription or the program is terminated by the sponsor. Initial dose RWJ-333369 is 1 capsule (250 milligram (mg) taken twice daily. Dosage may be changed at weekly intervals. The maximum permitted dose will be 4 capsules (1000 mg), twice daily during dose titration. Double blind-treatment duration is up to 71 days with the option to continue treatment in an open-label study. Maximum dose in open-label study is 1200 mg/day
CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.